Home
/
CUMBERLAND PHARMACEUTICALS INC
/
Financials
/
Quarterly
CUMBERLAND PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CUMBERLAND PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$8.29M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$10.84M
Aug 8, 2025
Q1
2025
Mar 31, 2025
$11.71M
May 9, 2025
Q3
2025
Sep 30, 2024
$9.09M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$9.85M
Aug 8, 2025
Q1
2025
Mar 31, 2024
$8.50M
May 9, 2025
Q3
2024
Sep 30, 2023
$10.09M
Nov 8, 2024
Q2
2024
Jun 30, 2023
$10.89M
Aug 9, 2024
Q1
2024
Mar 31, 2023
$9.22M
May 10, 2024
Q3
2023
Sep 30, 2022
$11.41M
Nov 13, 2023
Q2
2023
Jun 30, 2022
$10.30M
Aug 11, 2023
Q1
2023
Mar 31, 2022
$11.18M
May 12, 2023
Q3
2022
Sep 30, 2021
$8.07M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$9.06M
Aug 12, 2022
Q1
2022
Mar 31, 2021
$10.54M
May 13, 2022
Q3
2021
Sep 30, 2020
$9.25M
Nov 12, 2021
Q2
2020
Sep 30, 2020
$9.25M
Nov 13, 2020
Q2
2021
Jun 30, 2020
$9.60M
Aug 13, 2021
Q1
2021
Mar 31, 2020
$8.33M
May 14, 2021
Q2
2020
Sep 30, 2019
$6.94M
Nov 13, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2018
Jun 30, 2018
$10.16M
Aug 14, 2018
Q1
2018
Mar 31, 2018
$8.59M
May 9, 2018
Q3
2017
Sep 30, 2017
$11.20M
Nov 8, 2017
Q2
2018
Jun 30, 2017
$8.67M
Aug 14, 2018
Q1
2018
Mar 31, 2017
$9.64M
May 9, 2018
Q3
2017
Sep 30, 2016
$8.79M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$7.41M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$7.74M
May 15, 2017
Q3
2016
Sep 30, 2015
$7.89M
Nov 3, 2016
Q2
2016
Jun 30, 2015
$8.91M
Aug 5, 2016
Q1
2016
Mar 31, 2015
$8.69M
May 13, 2016
Q3
2015
Sep 30, 2014
$9.73M
Nov 6, 2015
Q2
2015
Jun 30, 2014
$9.75M
Aug 7, 2015
Q1
2015
Mar 31, 2014
$8.09M
May 15, 2015
Q3
2014
Sep 30, 2013
$6.53M
Nov 7, 2014
Q2
2014
Jun 30, 2013
$7.08M
Aug 8, 2014
Q1
2014
Mar 31, 2013
$10.26M
May 12, 2014
Q3
2013
Sep 30, 2012
$12.53M
Nov 6, 2013
Q2
2013
Jun 30, 2012
$12.37M
Aug 9, 2013
Q1
2013
Mar 31, 2012
$10.26M
May 8, 2013
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.94M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($740.7K)
Aug 8, 2025
Q1
2025
Mar 31, 2025
$1.26M
May 9, 2025
Q3
2025
Sep 30, 2024
($1.54M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($1.09M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($1.95M)
May 9, 2025
Q3
2024
Sep 30, 2023
($1.05M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
$872.2K
Aug 9, 2024
Q1
2024
Mar 31, 2023
$192.2K
May 10, 2024
Q3
2023
Sep 30, 2022
($408.6K)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($1.34M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($1.39M)
May 12, 2023
Q3
2022
Sep 30, 2021
($1.06M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
$1.23M
Aug 12, 2022
Q1
2022
Mar 31, 2021
$166.8K
May 13, 2022
Q3
2021
Sep 30, 2020
($481.7K)
Nov 12, 2021
Q2
2020
Sep 30, 2020
($481.7K)
Nov 13, 2020
Q2
2021
Jun 30, 2020
($918.3K)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($1.06M)
May 14, 2021
Q2
2020
Sep 30, 2019
($1.95M)
Nov 13, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.97M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($747.5K)
Aug 8, 2025
Q1
2025
Mar 31, 2025
$1.29M
May 9, 2025
Q3
2025
Sep 30, 2024
($1.69M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($1.03M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($1.87M)
May 9, 2025
Q3
2024
Sep 30, 2023
($1.87M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
$22.9K
Aug 9, 2024
Q1
2024
Mar 31, 2023
($1.53M)
May 10, 2024
Q3
2023
Sep 30, 2022
($288.6K)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($1.85M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($1.29M)
May 12, 2023
Q3
2022
Sep 30, 2021
($1.56M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($1.44M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($324.3K)
May 13, 2022
Q3
2021
Sep 30, 2020
($1.21M)
Nov 12, 2021
Q2
2020
Sep 30, 2020
($1.21M)
Nov 13, 2020
Q2
2021
Jun 30, 2020
($1.58M)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($1.85M)
May 14, 2021
Q2
2020
Sep 30, 2019
($3.20M)
Nov 13, 2020